FluoSphera
About FluoSphera
FluoSphera S.A. provides a chip-free, 3D cell culture platform that mimics human physiology to enable high-throughput, in vitro drug discovery. This technology allows researchers to rapidly evaluate drug efficacy and toxicity while reducing reliance on animal testing and minimizing pre-clinical costs.
```xml <problem> Traditional in vitro drug discovery methods often fail to accurately replicate the complex physiology of the human body, leading to inaccurate predictions of drug efficacy and toxicity. Reliance on animal testing increases costs and timelines, while also raising ethical concerns and potentially failing to translate to human outcomes. </problem> <solution> FluoSphera offers a chip-free, high-throughput 3D cell culture platform designed to mimic human physiology for improved in vitro drug discovery. The platform enables researchers to study the human response to systemic drug delivery with greater precision and speed. By recapitulating human first-pass liver Drug Metabolism and PharmacoKinetics (DMPK), the system allows for early detection of systemic drug effects typically observed only in animal models or patients. This approach facilitates rapid evaluation of drug efficacy and toxicity, reduces the need for animal testing, and optimizes pre-clinical testing strategies. The modular technology allows for individual project customization and the ability to evaluate over 1000 compounds with 28 simultaneous readouts. </solution> <features> - Chip-free 3D cell culture technology that mimics the natural physiology of the human body. - High-throughput screening capabilities for rapid evaluation of drug candidates. - Systemic exposure module that recapitulates human first-pass liver Drug Metabolism and PharmacoKinetics (DMPK). - Multiplexing technology allowing for >1000 compounds to be evaluated with 28 simultaneous readouts. - Modular technology allowing for individual project customization. </features> <target_audience> The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development. </target_audience> ```
What does FluoSphera do?
FluoSphera S.A. provides a chip-free, 3D cell culture platform that mimics human physiology to enable high-throughput, in vitro drug discovery. This technology allows researchers to rapidly evaluate drug efficacy and toxicity while reducing reliance on animal testing and minimizing pre-clinical costs.
Where is FluoSphera located?
FluoSphera is based in Geneva, United States.
When was FluoSphera founded?
FluoSphera was founded in 2024.
How much funding has FluoSphera raised?
FluoSphera has raised 111600.
- Location
- Geneva, United States
- Founded
- 2024
- Funding
- 111600
- Employees
- 4 employees
- Major Investors
- FONGIT Innovation Fund